Physician profile
Lori C Hemrock
NPI 1073517835
$6,590.12
in general payments reported to CMS, 2019-2025
56 companies · $1,328 in 2025
The $1,328 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $953 · 2020: $299 · 2021: $195 · 2022: $287 · 2023: $1,414 · 2024: $2,116 · 2025: $1,328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,781 · Education: $76.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,780.70 |
| Education | $76.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $448.12 | 2019-2025 | |
| Celgene Corporation | $443.34 | 2019-2025 | Opdivo, Reblozyl, Pomalyst |
| Pfizer INC. | $418.31 | 2020-2025 | |
| Asd Specialty Healthcare, LLC | $403.77 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $364.44 | 2019-2025 | Calquence, Lynparza, Imfinzi |
| Abbvie INC. | $357.46 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $306.34 | 2019-2025 | Keytruda, Reblozyl, Welireg |
| Astellas Pharma US INC | $305.51 | 2019-2025 | Padcev, Xtandi, Vyloy |
| E.R. Squibb & Sons, L.L.C. | $303.19 | 2019-2025 | Opdivo, Camzyos, Opdualag |
| Janssen Biotech, INC. | $273.76 | 2019-2025 | Darzalex, Rybrevant, Talvey |
| Genentech USA, INC. | $204.66 | 2019-2025 | Tecentriq, Venclexta, Polivy |
| Glaxosmithkline, LLC. | $193.36 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Eisai INC. | $182.17 | 2020-2025 | |
| Daiichi Sankyo INC. | $176.80 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Acrotech Biopharma INC. | $161.16 | 2021-2025 | Beleodaq |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $132.71 | 2019-2025 | Onivyde, Tazverik, Somatuline Depot |
| Incyte Corporation | $131.46 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Exelixis INC. | $125.94 | 2019-2025 | Cabometyx |
| Jazz Pharmaceuticals INC. | $121.46 | 2019-2024 | |
| Gilead Sciences, INC. | $117.13 | 2021-2025 | Trodelvy |
| Pharmacyclics LLC, An Abbvie Company | $93.71 | 2022-2023 | Imbruvica |
| Amgen INC. | $93.24 | 2019 | |
| Lilly USA, LLC | $88.42 | 2019-2025 | Retevmo, Verzenio, Jaypirca |
| Mirati Therapeutics, INC. | $82.52 | 2023-2024 | Krazati |
| Genmab U.S., INC. | $63.81 | 2023-2024 | Epkinly, Tivdak |
| Takeda Pharmaceuticals U.S.A., INC. | $63.13 | 2019-2024 | Alunbrig |
| Tempus Ai, INC | $62.75 | 2024-2025 | Xt Cdx |
| Genzyme Corporation | $61.21 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.61 | 2019-2023 | Gilotrif |
| Deciphera Pharmaceuticals INC. | $54.18 | 2023-2025 | Qinlock, Tgct |
| Karyopharm Therapeutics INC. | $53.98 | 2022-2024 | Xpovio |
| Array Biopharma INC | $48.76 | 2024-2025 | Braftovi, Lorbrena, Xalkori |
| Adc Therapeutics America, INC. | $47.38 | 2023 | |
| Aveo Pharmaceuticals, INC. | $46.18 | 2024 | |
| Janssen Pharmaceuticals, INC | $44.00 | 2024 | Rybrevant |
| Tactile Systems Technology INC | $43.48 | 2023 | Flexitouch Plus, Entre Plus |
| Bayer Healthcare Pharmaceuticals INC. | $38.80 | 2019-2024 | |
| Seagen INC. | $36.38 | 2019-2023 | Tukysa |
| Dendreon Pharmaceuticals LLC | $34.83 | 2025 | Provenge |
| Emd Serono, INC. | $24.24 | 2023 | Tepmetko |
| Mylan Institutional INC. | $24.19 | 2023 | Fulphila |
| Alexion Pharmaceuticals, INC. | $24.11 | 2025 | Ultomiris |
| Beone Medicines USA, INC. | $22.35 | 2025 | Brukinsa |
| Blueprint Medicines Corporation | $20.39 | 2023 | Ayvakit |
| Apellis Pharmaceuticals, INC. | $19.06 | 2024 | Empaveli |
| Kyowa Kirin, INC. | $18.80 | 2025 | |
| Geron Corporation | $17.99 | 2025 | Rytelo |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
| Sun Pharmaceutical Industries INC. | $16.53 | 2023 | Odomzo, Yonsa |
| Invivyd INC | $16.38 | 2025 | Pemgarda |
| Taiho Oncology, INC. | $15.00 | 2019 | |
| Adaptive Biotechnologies Corporation | $14.86 | 2022 | |
| Verity Pharmaceuticals INC. | $14.52 | 2024 | Trelstar |
| Tesaro, INC. | $14.48 | 2019 | |
| Kite Pharma, INC. | $13.51 | 2025 | Yescarta |
| Morphosys, US INC. | $13.23 | 2023 | Monjuvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Hemrock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.